nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT02693535,Targeted Agent and Profiling Utilization Registry (TAPUR) Study,Phase 2,Recruiting,Interventional,"Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors",Palbociclib; Sunitinib; Temsirolimus; Trastuzumab and Pertuzumab; Vemurafenib and Cobimetinib; Regorafenib; Olaparib; Pembrolizumab; Nivolumab and Ipilimumab; Abemaciclib; Talazoparib; Atezolizumab and PHESGO; Atezolizumab and Talazoparib; Entrectinib; Larotrectinib; Tucatinib plus Trastuzumab Subcutaneous (SC); Futibatinib,,American Society of Clinical Oncology,"AstraZeneca; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; Genentech, Inc.; Merck Sharp & Dohme LLC; Pfizer; Boehringer Ingelheim; Seagen Inc.; Taiho Oncology, Inc.",4200,2016-03-14,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT02693535
NCT03011684,Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial,Phase 3,Recruiting,Interventional,Infertility,Tamoxifen; Letrozole,,"University of California, San Francisco",,309,2016-07-21,2026-03-31,United States,No,https://clinicaltrials.gov/study/NCT03011684
NCT03675893,"RESOLVE: letRozole abEmaciclib combinationS in endOmetriaL and oVarian cancEr: A Multi-Cohort Phase 2 Study of Letrozole/Abemaciclib Alone and in Combination With Metformin, Zotatifin and Gedatolisib",Phase 2,Recruiting,Interventional,Endometrial Cancer; Ovarian Cancer,Letrozole; Abemaciclib; LY3023414; Metformin; Zotatifin; Gedatolisib,,Dana-Farber Cancer Institute,Eli Lilly and Company; Effector Therapeutics; Celcuity Inc,180,2018-12-24,2031-08-01,United States,No,https://clinicaltrials.gov/study/NCT03675893
NCT03740256,A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors,Phase 1,Recruiting,Interventional,Bladder Cancer; Head and Neck Squamous Cell Carcinoma; Cancer of the Salivary Gland; Lung Cancer; Breast Cancer; Gastric Cancer; Esophageal Cancer; Colorectal Cancer; Pancreatic Adenocarcinoma; Solid Tumor,CAdVEC,,Baylor College of Medicine,The Methodist Hospital Research Institute,45,2020-12-14,2038-12-30,United States,No,https://clinicaltrials.gov/study/NCT03740256
NCT03769415,HARMONY: Harnessing the Analysis of RNA Expression and Molecular Subtype to Optimize Novel TherapY for Metastatic Breast Cancer,Not Applicable,Recruiting,Interventional,Breast Cancer,Intrinsic Subtyping of Primary Breast Cancer,,UNC Lineberger Comprehensive Cancer Center,"Veracyte, Inc.; Breast Cancer Research Foundation",500,2018-11-06,2030-12-15,United States,No,https://clinicaltrials.gov/study/NCT03769415
NCT03909282,A Randomized Phase II Study Comparing Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS),Not Applicable,Recruiting,Interventional,Ductal Breast Carcinoma in Situ,Lumpectomy; Partial breast irradiation prior to surgery,,Stanford University,,50,2019-03-22,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT03909282
NCT03971409,"Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study",Phase 2,Recruiting,Interventional,Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Invasive Breast Carcinoma; Recurrent Breast Carcinoma; Triple-Negative Breast Carcinoma; Unresectable Breast Carcinoma,Anti-OX40 Antibody PF-04518600; Avelumab; Binimetinib; Utomilumab; Liposomal Doxorubicin; Sacituzumab Govitecan,,"Laura Huppert, MD, BA",Translational Breast Cancer Research Consortium; Hoosier Cancer Research Network; Array BioPharma; Pfizer; Breast Cancer Research Foundation; Johns Hopkins University; Gilead Sciences,150,2019-07-08,2026-06-30,United States,No,https://clinicaltrials.gov/study/NCT03971409
NCT04234048,"A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion",Phase 1,Recruiting,Interventional,"T-cell Lymphoma; Cutaneous/Peripheral T-Cell Lymphoma; Peripheral T-cell Lymphoma; Peripheral T-Cell Lymphoma, Not Classified; Primary Cutaneous T-cell Lymphoma; Cutaneous T-Cell Lymphoma, Unspecified; Cutaneous T-cell Lymphoma; Follicular T-Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Sézary's Disease; Mycosis Fungoides",Fenretinide,,"SciTech Development, Inc.",,46,2023-12-18,2027-05-01,United States,No,https://clinicaltrials.gov/study/NCT04234048
NCT04250259,"A Multi-center, Randomized, Placebo-controlled Trial of S-Adenosylmethionine (SAMe) in Patients With Alcoholic Cirrhosis",Phase 2,Recruiting,Interventional,Alcoholic Cirrhosis,Placebo; SAMe 400 mg tablet,,Indiana University,Cedars-Sinai Medical Center; National Institute on Alcohol Abuse and Alcoholism (NIAAA),196,2020-10-22,2027-03-01,United States,No,https://clinicaltrials.gov/study/NCT04250259
NCT04553770,"A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting",Phase 2,Recruiting,Interventional,Early-stage Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Invasive Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer,Anastrozole; Therapeutic Conventional Surgery; Trastuzumab Deruxtecan,,Jonsson Comprehensive Cancer Center,"Translational Research in Oncology-U.S; Daiichi Sankyo Co., Ltd.",88,2020-10-09,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT04553770
NCT04563507,CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer,Phase 2,Recruiting,Interventional,Breast Cancer,Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions); Letrozole 2.5Mg Tab; Palbociclib 125mg,,Weill Medical College of Cornell University,,102,2020-11-12,2028-10-31,United States,No,https://clinicaltrials.gov/study/NCT04563507
NCT04568616,Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI),Phase 2,Recruiting,Interventional,Breast Cancer; ER Positive Breast Cancer,Letrozole 2.5mg,,Dartmouth-Hitchcock Medical Center,,137,2021-08-13,2029-08-13,United States,No,https://clinicaltrials.gov/study/NCT04568616
NCT04573231,"Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET/CT",Phase 2,Recruiting,Interventional,Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,18F-DCFPyL,,"University of Wisconsin, Madison",,13,2021-05-24,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT04573231
NCT04585750,"A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Cancer; Ovarian Cancer; Endometrial Cancer; Prostate Cancer; Colorectal Cancer; Breast Cancer; Other Cancer; Locally Advanced; Head and Neck Cancer; Gall Bladder Cancer; Small Cell Lung Cancer; Small Cell Lung Cancer ( SCLC ); Small Cell Lung Carcinoma; NSCLC; NSCLC (Non-small Cell Lung Cancer); SCLC; Non-Small Cell Lung Carcinoma; Triple Negative Breast Cancer; TNBC; HER2+ Breast Cancer; Non-Small Cell Lung Cancer; ER/PR Positive Breast Cancer; HER2- Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; ER/PR(+), Her2(-) Breast Cancer",rezatapopt; pembrolizumab,,"PMV Pharmaceuticals, Inc",Merck Sharp & Dohme LLC,300,2020-10-29,2027-12-31,Australia; France; Germany; Italy; Singapore; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04585750
NCT04609592,"Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery",Phase 1,Recruiting,Interventional,Gastroenteropancreatic Neuroendocrine Tumor,Lutathera; Gallium 68 Dotatate; Computed Tomography (CT); Magnetic Resonance Imaging (MRI); PET/CT,,Stanford University,Novartis Pharmaceuticals,10,2021-03-17,2027-09-05,United States,No,https://clinicaltrials.gov/study/NCT04609592
NCT04744116,A Randomized Controlled Pilot Study of Two Doses of Cord Blood Tissue-Derived Mesenchymal Stromal Cells Combined With Ruxolitinib Versus Ruxolitinib Alone for Therapy of Steroid-Refractory Acute Graft Versus Host Disease,Early Phase 1,Recruiting,Interventional,Hematopoietic and Lymphoid Cell Neoplasm; Steroid Refractory Graft Versus Host Disease,Cellular Therapy; Ruxolitinib,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),24,2021-02-17,2026-03-15,United States,No,https://clinicaltrials.gov/study/NCT04744116
NCT04771130,"A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Acute Myeloid Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasm,BGB-11417; Azacitidine; Posaconazole; BGB-11417; BGB-11417,,BeiGene,,260,2021-05-24,2028-02-08,Australia; China; France; Germany; Italy; New Zealand; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04771130
NCT04802759,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)",Phase 1/Phase 2,Recruiting,Interventional,"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",Giredestrant; Abemaciclib; Ipatasertib; Inavolisib; Ribociclib; Everolimus; Samuraciclib; PH FDC SC; Palbociclib; Atezolizumab,,Hoffmann-La Roche,,316,2021-06-22,2029-05-30,Australia; Israel; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT04802759
NCT04844528,Randomized Phase 2 Studying the Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC),Phase 2,Recruiting,Interventional,Chronic Lymphocytic Leukemia; Non-melanoma Skin Cancer (NMSC),Nicotinamide; Placebo,,University of Utah,Huntsman Cancer Institute,86,2022-02-25,2028-08-05,United States,No,https://clinicaltrials.gov/study/NCT04844528
NCT04862663,"A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)",Phase 3,Recruiting,Interventional,Locally Advanced (Inoperable) or Metastatic Breast Cancer,Capivasertib; Fulvestrant; Palbociclib; Ribociclib; Abemaciclib,,AstraZeneca,,895,2021-05-10,2029-08-14,Argentina; Australia; Belgium; Brazil; Canada; China; Denmark; France; Germany; India; Italy; Japan; Malaysia; Poland; South Korea; Spain; Sweden; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT04862663
NCT04872166,"An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX A51 Alone and in Combination With Fulvestrant in Subjects With Advanced Solid Tumors and Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Metastatic Breast Cancer,BTX-A51,,Edgewood Oncology Inc.,,112,2021-06-07,2027-05-05,United States,No,https://clinicaltrials.gov/study/NCT04872166
NCT04883437,"An Open-Label Phase 2 Trial of Acalabrutinib Plus Obinutuzumab in Patients with Untreated, Low Tumor Burden Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas",Phase 2,Recruiting,Interventional,Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Indolent Non-Hodgkin Lymphoma; Lymphoplasmacytic Lymphoma; Lymphoproliferative Disorder; Mantle Cell Lymphoma; Marginal Zone Lymphoma,Acalabrutinib; Obinutuzumab; Quality-of-Life Assessment; Questionnaire Administration,,Emory University,AstraZeneca; National Cancer Institute (NCI),49,2021-09-03,2026-01-15,United States,No,https://clinicaltrials.gov/study/NCT04883437
NCT04886531,"An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Cancers Hoosier Cancer Research Network BRE17-141",Phase 2,Recruiting,Interventional,Breast Cancer; HER2-positive Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer,Neratinib; Letrozole (L) or Anastrozole (A); Trastuzumab,,Ruth O'Regan,"Puma Biotechnology, Inc.; University of Rochester",30,2022-07-21,2026-01-05,United States,No,https://clinicaltrials.gov/study/NCT04886531
NCT04899908,"A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone",Phase 2,Recruiting,Interventional,Brain Cancer; Brain Metastases; Melanoma; Lung Cancer; Breast Cancer; HER2-positive Breast Cancer; Colorectal Cancer; Gastrointestinal Cancer; SRS; SRT; Whole Brain Radiation; Stereotactic Radiation; AGuIX; Nanoparticle; Cystic; Brain Tumor,Stereotactic Radiation; AGuIX gadolinium-based nanoparticles; Placebo,,Dana-Farber Cancer Institute,NH TherAguix SAS,134,2021-09-15,2026-02-05,United States,No,https://clinicaltrials.gov/study/NCT04899908
NCT04995003,Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0),Phase 1,Recruiting,Interventional,Sarcoma; HER-2 Protein Overexpression; Osteosarcoma; Rhabdomyosarcoma; Ewing Sarcoma; Synovial Sarcoma; Soft Tissue Sarcoma; Undifferentiated Sarcoma,T cells or CAR T cells; Pembrolizumab Injectable Product; Nivolumab Injectable Product,,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine; The Faris Foundation USA; Stand Up To Cancer; Triumph Over Kid Cancer Foundation; St. Baldrick's Foundation; National Cancer Institute (NCI)",25,2021-12-07,2040-12-31,United States,No,https://clinicaltrials.gov/study/NCT04995003
NCT05013632,COVID-19 International Drug Pregnancy Registry (COVID-PR),,Recruiting,Observational,Covid19,Antiviral Agents; Monoclonal antibody,,Pregistry,,2000,2021-12-01,2027-09-30,United States,No,https://clinicaltrials.gov/study/NCT05013632
NCT05053607,"Clinical and Patient Reported Outcomes for Individuals with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab: Real-World Insights from Patient Reported, Wearable, and Qualitative Data in the Context of Digital Health Coaching",Not Applicable,Recruiting,Interventional,Multiple Myeloma; Refractory Multiple Myeloma,Digital Health Coaching Program; Fitbit,,Pack Health,M.D. Anderson Cancer Center; Sanofi; University of Washington,50,2022-06-17,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT05053607
NCT05134012,"A Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered [15-O]-H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Conditions Using PET Imaging (RAPID-WATER-FLOW)",Phase 3,Recruiting,Interventional,Coronary Artery Disease,[O-15]-Water PET Myocardial Perfusion Imaging (MPI),,MedTrace Pharma A/S,,215,2022-05-08,2026-12-31,Canada; Denmark; Germany; Netherlands; Sweden; United States,No,https://clinicaltrials.gov/study/NCT05134012
NCT05150652,"Phase 2 Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer",Phase 2,Recruiting,Interventional,Breast Cancer; HER2-negative Breast Cancer; Node-negative Breast Cancer; Breast Carcinoma,Anastrozole 1mg; Letrozole 2.5mg; Exemestane 25 mg; Tamoxifen,,Irada Ibrahim-zada,,70,2022-02-18,2036-10-05,United States,No,https://clinicaltrials.gov/study/NCT05150652
NCT05183230,WellPATH-PREVENT: A Mobile Intervention for Middle-Aged and Older Adults Hospitalized for Suicidal Ideation or Attempt,Not Applicable,Recruiting,Interventional,"Suicide, Attempted; Suicidal Ideation; Depression",WellPATH-PREVENT; Optimized WellPATH-PREVENT,,Weill Medical College of Cornell University,National Institute of Mental Health (NIMH),115,2022-04-22,2026-09-30,United States,No,https://clinicaltrials.gov/study/NCT05183230
NCT05187182,Phase I Trial of CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer,Phase 1,Recruiting,Interventional,Gastric Cancer; Esophageal Cancer; Stomach Cancer; Esophagus Cancer; Gastroesophageal Junction Cancer,CA-4948; Nivolumab; Pembrolizumab; Trastuzumab; mFOLFOX7,,Washington University School of Medicine,"Curis, Inc.; The Foundation for Barnes-Jewish Hospital",42,2023-06-02,2028-06-30,United States,No,https://clinicaltrials.gov/study/NCT05187182
NCT05187832,A Phase I Dose Escalation and Dose Expansion Study of AND019 in Patients With Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Advanced or Metastatic Breast Cancer,Phase 1,Recruiting,Interventional,Advanced or Metastatic Breast Cancer,AND019 PO QD,,Kind Pharmaceuticals LLC,,61,2022-10-05,2026-05-05,United States,No,https://clinicaltrials.gov/study/NCT05187832
NCT05230810,"This is a Multicenter, Single Arm, Open-label, run-in Phase Ib / Roll-over Phase II Study of Tucatinib in Combination With Alpelisib in Subjects With PIK3CA-mutant HER2-positive Locally Advanced Unresectable or Metastatic Breast Cancer.",Phase 1/Phase 2,Recruiting,Interventional,HER2-positive Metastatic Breast Cancer,Alpelisib; Tucatinib; Fulvestrant,,"Criterium, Inc.",Novartis; Seagen Inc.,40,2022-08-25,2025-06-30,United States,No,https://clinicaltrials.gov/study/NCT05230810
NCT05232916,"A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)",Phase 3,Recruiting,Interventional,Breast Cancer,Placebo; GLSI-100,,"Greenwich LifeSciences, Inc.",,750,2022-08-11,2026-12-05,France; Germany; Ireland; Italy; Poland; Romania; Spain; United States,No,https://clinicaltrials.gov/study/NCT05232916
NCT05256225,"A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma",Phase 3,Recruiting,Interventional,Endometrial Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Uterine Corpus Carcinosarcoma,Biospecimen Collection; Carboplatin; Computed Tomography; Echocardiography Test; High-Dose-Rate Vaginal Cuff Brachytherapy; Hyaluronidase-zzxf/Pertuzumab/Trastuzumab; Multigated Acquisition Scan; Paclitaxel; Survey Administration; Trastuzumab/Hyaluronidase-oysk,,National Cancer Institute (NCI),NRG Oncology,360,2022-11-16,2027-10-31,Puerto Rico; South Korea; United States,No,https://clinicaltrials.gov/study/NCT05256225
NCT05325632,"A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed Dendritic Cell (DC1) Vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer",Phase 2,Recruiting,Interventional,HER2-positive Breast Cancer,HER-2 pulsed DC1; Trastuzumab; Pertuzumab; Paclitaxel; Resection surgery,,H. Lee Moffitt Cancer Center and Research Institute,ImmunoRestoration,53,2021-10-28,2026-09-05,United States,No,https://clinicaltrials.gov/study/NCT05325632
NCT05386108,"An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer",Phase 1/Phase 2,Recruiting,Interventional,Breast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Central Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases,Elacestrant; Abemaciclib,,"Stemline Therapeutics, Inc.",,73,2022-08-31,2026-12-05,Belgium; France; Germany; Greece; Italy; South Korea; Spain; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05386108
NCT05405595,"A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced/Metastatic Solid Tumors,ADG126; Pembrolizumab (KEYTRUDA®); Standard of Care (Trifluridine/Tipiracil-Bevacizumab); Standard of care (Fruquintinib),,Adagene Inc,Merck Sharp & Dohme LLC,152,2022-06-15,2027-04-30,China; South Korea; United States,No,https://clinicaltrials.gov/study/NCT05405595
NCT05417594,"A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Malignancies,AZD9574; Temozolomide (TMZ); [11C]AZ1419 3391; Trastuzumab Deruxtecan (T-DXd); Datopotamab Deruxtecan (Dato-DXd),,AstraZeneca,,695,2022-06-24,2027-08-11,Australia; Germany; South Korea; Spain; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05417594
NCT05455619,"Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt Inhibitor Plus Fulvestrant in Patients With HR+, HER2-, Metastatic Breast Cancer With PI3K Pathway Alteration(s)",Phase 1/Phase 2,Recruiting,Interventional,HR+/HER2-negative Breast Cancer; Metastatic Breast Cancer,Evexomostat,,"SynDevRx, Inc.",,52,2022-08-26,2026-09-05,United States,No,https://clinicaltrials.gov/study/NCT05455619
NCT05463263,"An Open-Label, First in Human, Phase 1/2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas",Phase 1/Phase 2,Recruiting,Interventional,"Lymphoma, B-Cell; Lymphoma, T-Cell",STP938,,"Step Pharma, SAS",,180,2022-08-03,2025-12-05,France; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05463263
NCT05504707,"Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)",Phase 1,Recruiting,Interventional,Triple Negative Breast Cancer; HER2-negative Breast Cancer,HER2 - primed Dendritic cells; HER3 - primed Dendritic cells,,H. Lee Moffitt Cancer Center and Research Institute,The Shulas' Foundation,30,2022-08-26,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT05504707
NCT05508906,"A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, With the mTOR Inhibitor Everolimus, or With CDK4 Inhibitor Atirmociclib in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer",Phase 1,Recruiting,Interventional,Metastatic Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Breast Cancer; Locally Advanced Breast Cancer,Palazestrant; Ribociclib; Alpelisib; Everolimus; Atirmociclib,,"Olema Pharmaceuticals, Inc.",Novartis; Pfizer,190,2022-08-31,2028-01-31,Australia; United States,No,https://clinicaltrials.gov/study/NCT05508906
NCT05544019,"A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies",Phase 1,Recruiting,Interventional,"Mature B-Cell Neoplasm; Non Hodgkin Lymphoma; DLBCL; Waldenstrom Macroglobulinemia; MALT Lymphoma; Follicular Lymphoma; Pediatric-Type Follicular Lymphoma; IRF4 Gene Rearrangement; EBV-Positive DLBCL, Nos; Burkitt Lymphoma; Plasmablastic Lymphoma; High-grade B-cell Lymphoma; Primary Cutaneous Follicle Center Lymphoma; Primary Effusion Lymphoma; Mantle Cell Lymphoma; DLBCL Germinal Center B-Cell Type; Primary Mediastinal Large B Cell Lymphoma; T-Cell/Histiocyte Rich Lymphoma; ALK-Positive Large B-Cell Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma; Splenic Marginal Zone Lymphoma; Chronic Lymphocytic Leukemia; Nodal Marginal Zone Lymphoma; HHV8-Positive DLBCL, Nos; Lymphoplasmacytic Lymphoma; Duodenal-Type Follicular Lymphoma",SGR-1505,,"Schrödinger, Inc.",,52,2023-04-10,2026-03-05,France; Italy; Moldova; Poland; Romania; Spain; Ukraine; United States,No,https://clinicaltrials.gov/study/NCT05544019
NCT05557877,Targeted Prevention of Postpartum-Related Breast Cancer,Phase 2,Recruiting,Interventional,Breast Carcinoma,Biospecimen Collection; Low-Dose Aspirin; Questionnaire Administration; Biopsy,,Mayo Clinic,National Cancer Institute (NCI),100,2023-03-09,2027-01-30,United States,No,https://clinicaltrials.gov/study/NCT05557877
NCT05563220,"A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer",Phase 1/Phase 2,Recruiting,Interventional,Breast Cancer; Metastatic Breast Cancer,Elacestrant; Alpelisib; Everolimus; Ribociclib; Palbociclib; Capivasertib; Abemaciclib,,"Stemline Therapeutics, Inc.",,435,2023-01-24,2028-12-28,Argentina; Australia; Belgium; Brazil; Czechia; France; Germany; Hungary; Israel; Italy; Luxembourg; Poland; South Korea; Spain; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05563220
NCT05573126,"A Modular, Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 as Monotherapy and in Combination in Patients With Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer",Phase 1/Phase 2,Recruiting,Interventional,Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer,Vosilasarm; Elacestrant; Everolimus,,Ellipses Pharma,,60,2023-01-11,2026-11-05,Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05573126
NCT05579366,Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC); Mesothelioma; Breast Adenocarcinoma; Triple Negative Breast Cancer; Hormone Receptor-positive/Her2 Negative Breast Cancer; Platinum-resistant Ovarian Cancer (PROC); Platinum Sensitive Ovarian Cancer (PSOC); Primary Refractory Ovarian Cancer; Uterine Cancer,Rina-S; Carboplatin; Bevacizumab; Pembrolizumab,,Genmab,,764,2022-12-07,2027-10-05,China; Japan; United States,No,https://clinicaltrials.gov/study/NCT05579366
NCT05608252,A Single Arm Phase 1/2 Trial of Abemaciclib + VS-6766 + Fulvestrant in Metastatic HR+/HER2- Breast Cancer,Phase 1/Phase 2,Recruiting,Interventional,Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer,VS-6766; Abemaciclib; Fulvestrant,,Adrienne G. Waks,"Verastem, Inc.; Eli Lilly and Company",63,2023-02-23,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT05608252
NCT05696626,"An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation",Phase 3,Recruiting,Interventional,Metastatic Breast Cancer,Lasofoxifene in combination with abemaciclib; Fulvestrant in combination with abemaciclib,,Sermonix Pharmaceuticals Inc.,,500,2023-10-31,2028-04-05,Australia; Belgium; Canada; China; France; Germany; Israel; Italy; Poland; Romania; Singapore; South Korea; Spain; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05696626
NCT05748834,Phase 2 Single Arm Trial With a Safety Lead-in of Tucatinib in Combination With Doxil for the Treatment of HER2+ Metastatic Breast Cancer,Phase 2,Recruiting,Interventional,Breast Cancer,Tucatinib; Doxil,,"SCRI Development Innovations, LLC",Seagen Inc.; Pfizer,36,2023-07-24,2026-07-05,United States,No,https://clinicaltrials.gov/study/NCT05748834
NCT05783609,A Phase 2 Study of Epcoritamab and Rituximab for First-line Treatment of Follicular Lymphoma,Phase 2,Recruiting,Interventional,"Follicular Lymphoma; Low Grade Non-Hodgkin's Lymphoma, Adult",Epcoritamab; Rituximab,,"Reid Merryman, MD",Genmab; AbbVie,100,2023-06-21,2030-02-05,United States,No,https://clinicaltrials.gov/study/NCT05783609
NCT05798897,A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO),Phase 1,Recruiting,Interventional,"Non-Hodgkin Lymphoma, Adult; Non-Hodgkin Lymphoma, Refractory; Non-Hodgkin Lymphoma, Relapsed; Non Hodgkin Lymphoma; Hodgkin Lymphoma; Hodgkin Lymphoma, Adult; Hodgkin's Lymphoma, Relapsed, Adult",MT-601,,"Marker Therapeutics, Inc.",,79,2023-01-02,2028-02-28,United States,No,https://clinicaltrials.gov/study/NCT05798897
NCT05826964,"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer: A Phase 2 Randomized, Open-Label Study",Phase 2,Recruiting,Interventional,Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer,AI+CDK4/6i; SERD+CDK4/6i; mTOR inhibitor + AI; mTOR inhibitor + SERD; mTOR inhibitor + Selective estrogen receptor modulator; PI3K inhibitor + SERD; PI3K inhibitor + AI; Chemotherapy; Oral SERD; PARPi; AKT inhibitor; Step 3 Arm 2,,University of Miami,,500,2023-06-12,2029-07-31,United States,No,https://clinicaltrials.gov/study/NCT05826964
NCT05853575,A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2,Recruiting,Interventional,Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung,Adagrasib,,Mirati Therapeutics Inc.,,200,2024-02-16,2026-07-30,Brazil; Croatia; France; Greece; Hungary; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Romania; Serbia; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT05853575
NCT05874193,A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma,Phase 2,Not yet recruiting,Interventional,Relapsed/Refractory Multiple Myeloma,Belantamab mafodotin,,"Cristiana Costa Chase, DO",,33,2025-10-05,2027-10-05,United States,No,https://clinicaltrials.gov/study/NCT05874193
NCT05879926,"A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)",Phase 3,Recruiting,Interventional,Breast Cancer,Ovarian Function Suppression + Aromatase Inhibitor; Adjuvant Chemotherapy + Ovarian Function Suppression,,NRG Oncology,National Cancer Institute (NCI),3960,2023-08-31,2034-07-05,Canada; Colombia; Japan; Mexico; Peru; Puerto Rico; United States; Uruguay,No,https://clinicaltrials.gov/study/NCT05879926
NCT05888493,"A Randomized, Open-label, Multi-center Phase III Trial Comparing Tisagenlecleucel to Standard of Care in Adult Participants With Relapsed or Refractory Follicular Lymphoma (FL)",Phase 3,Recruiting,Interventional,Follicular Lymphoma (FL),"Tisagenlecleucel; Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.; Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles; Lymphodepleting chemotherapy; Corticosteroids and/or Radiation (Bridging therapy)",,Novartis Pharmaceuticals,,108,2023-10-02,2031-01-18,Australia; Austria; Canada; Czechia; Hungary; Poland; Romania; Singapore; Slovakia; South Korea; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT05888493
NCT05894239,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer",Phase 3,Recruiting,Interventional,Metastatic Breast Cancer,Inavolisib; Phesgo; Placebo; Taxane-based Chemotherapy; Optional Endocrine Therapy of Investigator's Choice,,Hoffmann-La Roche,,230,2023-09-08,2032-12-28,Argentina; Australia; Belgium; Brazil; Canada; China; Colombia; Finland; France; Germany; Hong Kong; India; Italy; Jordan; Kenya; Mexico; Oman; Poland; Singapore; South Africa; South Korea; Spain; Taiwan; Tunisia; Turkey (Türkiye); Uganda; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05894239
NCT05903092,A Phase II Trial of MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART),Phase 2,Recruiting,Interventional,Small Cell Lung Cancer; SCLC; Extensive Stage Small Cell Lung Cancer,Durvalumab; Monalizumab; Carboplatin or Cisplatin; Etoposide,,Hirva Mamdani,AstraZeneca; Barbara Ann Karmanos Cancer Institute,38,2023-09-26,2027-01-03,United States,No,https://clinicaltrials.gov/study/NCT05903092
NCT05916196,[18F]FLUOROESTRADIOL (FES) PET/CT IMAGING OF THE ESTROGEN RECEPTOR IN PATIENTS WITH METASTATIC OR RECURRENT UTERINE CANCER,Phase 2,Recruiting,Interventional,Uterine Cancer,18F-Fluoroestradiol,,Abramson Cancer Center at Penn Medicine,,30,2024-04-05,2027-08-01,United States,No,https://clinicaltrials.gov/study/NCT05916196
NCT05950945,"A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)",Phase 3,Recruiting,Interventional,Breast Cancer,Trastuzumab Deruxtecan,,Daiichi Sankyo,AstraZeneca,250,2023-12-30,2027-10-01,Australia; Belgium; Brazil; China; Ireland; Italy; Netherlands; Portugal; Spain; United States,No,https://clinicaltrials.gov/study/NCT05950945
NCT05978518,Feasibility and Efficacy Study of the CardioPulmonary Monitoring (CPM) System in Patients With Chronic Heart Failure,Phase 2/Phase 3,Recruiting,Interventional,Heart Failure,CPM Device + Monitoring; CPM Device,,"Analog Device, Inc.",,100,2023-07-13,2025-12-20,United States,No,https://clinicaltrials.gov/study/NCT05978518
NCT05985655,"A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma (HNSCC); Pancreatic Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC); Breast Carcinoma; High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC); Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma",GTAEXS617; SoC,,"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",,165,2023-07-06,2028-05-05,Belgium; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05985655
NCT05989828,Phase Ib Clinical Trial of Autologous Anti-NY-ESO-1 TCR-Engineered T Cells in Patients With Relapsed/Refractory Locally Advanced or Metastatic NY-ESO-1-Expressing Triple Negative Breast Cancer,Phase 1,Recruiting,Interventional,Triple Negative Breast Cancer,Aldesleukin; Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes; Biopsy; Biospecimen Collection; Computed Tomography; Cyclophosphamide; Echocardiography; Fludarabine; Leukapheresis; Magnetic Resonance Imaging; Mammogram; Multigated Acquisition Scan; Ultrasound Imaging,,University of Southern California,National Cancer Institute (NCI),20,2024-12-17,2027-12-17,United States,No,https://clinicaltrials.gov/study/NCT05989828
NCT06007131,Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure,Not Applicable,Recruiting,Interventional,Heart Failure,CardioPumlonary Management System,,"Analog Device, Inc.","Orlando Health, Inc.",75,2023-12-15,2025-11-01,United States,No,https://clinicaltrials.gov/study/NCT06007131
NCT06016738,"A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)",Phase 3,Recruiting,Interventional,Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma,Palazestrant; Fulvestrant; Anastrozole; Letrozole; Exemestane,,"Olema Pharmaceuticals, Inc.",,510,2023-11-16,2027-09-30,Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Czechia; France; Germany; Hong Kong; Hungary; Italy; Malaysia; Mexico; Netherlands; Poland; Portugal; Puerto Rico; Romania; South Korea; Spain; Taiwan; Thailand; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06016738
NCT06028022,Reishi Mushroom Extract for Fatigue and/or Arthralgias in Patients With Breast Cancer on Aromatase Inhibitors: A Randomized Phase II MNCCTN Trial,Phase 2,Recruiting,Interventional,Estrogen Receptor-Positive Breast Carcinoma,Mushroom Extract; Placebo Administration; Quality-of-Life Assessment; Questionnaire Administration,,Mayo Clinic,,80,2023-10-18,2026-10-16,United States,No,https://clinicaltrials.gov/study/NCT06028022
NCT06035744,"A Phase 1 First-in-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor,CLN-617; Pembrolizumab,,Cullinan Therapeutics Inc.,,86,2023-12-12,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT06035744
NCT06055881,Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS),Not Applicable,Recruiting,Interventional,Breast Carcinoma; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Cancer,Biospecimen Collection; Surveys; Stereotactic Body Radiation Therapy (SBRT); Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography,,Mayo Clinic,,45,2023-10-23,2032-05-01,United States,No,https://clinicaltrials.gov/study/NCT06055881
NCT06058377,Phase III Trial Of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone For Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer,Phase 3,Recruiting,Interventional,Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma,Biospecimen Collection; Cyclophosphamide; Doxorubicin; Durvalumab; Genetic Testing; Mammography; Paclitaxel; Quality-of-Life Assessment,,National Cancer Institute (NCI),,3680,2023-11-27,2026-05-31,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06058377
NCT06062498,"Randomized Phase II Study of Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) in Patients With ER+/HER2- Advanced or Metastatic Breast Cancer With Prior Exposure to a CKD4/6 Inhibitor",Phase 2,Recruiting,Interventional,Estrogen-receptor-positive Breast Cancer; HER2/Neu-Negative Breast Cancer; Advanced Breast Cancerv; Metastatic Breast Cancer,"elacestrant, palbociclib, abemaciclib, ribociclib",,Northwestern University,National Cancer Institute (NCI),174,2023-09-29,2027-07-01,United States,No,https://clinicaltrials.gov/study/NCT06062498
NCT06099769,"A RANDOMIZED, PHASE II STUDY OF ENZALUTAMIDE, ENZALUTAMIDE WITH MIFEPRISTONE, and TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH AR+ METASTATIC TRIPLE-NEGATIVE OR ER-LOW BREAST CANCER",Phase 2,Recruiting,Interventional,Metastatic Breast Cancer,Enzalutamide; Mifepristone; TPC,,Memorial Sloan Kettering Cancer Center,"Astellas Pharma US, Inc.; Breast Cancer Research Foundation; Corcept Therapeutics",201,2023-10-18,2027-10-05,United States,No,https://clinicaltrials.gov/study/NCT06099769
NCT06119581,"SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis",LY3537982; Pembrolizumab; Placebo; Cisplatin; Carboplatin; Pemetrexed,,Eli Lilly and Company,,1016,2023-12-21,2029-10-05,Australia; Austria; Belgium; Brazil; Canada; China; Czechia; Denmark; France; Germany; Greece; Hungary; India; Italy; Japan; Mexico; Netherlands; Norway; Poland; Portugal; Romania; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06119581
NCT06139107,RADIANT Study: Pre-op Radiation With Abemaciclib Andletrozole in Early Stage Breast Cancer,Phase 1,Recruiting,Interventional,Breast Cancer,Abemaciclib; Letrozole,,"Mridula George, MD",,15,2024-08-22,2032-09-30,United States,No,https://clinicaltrials.gov/study/NCT06139107
NCT06149481,"Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Colorectal Cancer,"Retifanlimab; Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform; N-803; SX-682",,National Cancer Institute (NCI),,60,2024-03-26,2030-10-31,United States,No,https://clinicaltrials.gov/study/NCT06149481
NCT06154590,"Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer (Clinical Studies), Tamoxifen Citrate Was Added to Adjunct Cytotoxic Chemotherapy- Treatment of Malignant Joint Tumor.",,Not yet recruiting,Observational,Metastatic Breast Cancer; Tumor; Muscle Neoplasms; Chronic Pain,"Method(s)1 Attribution; Method(s)2 Attribution,",,DR. DIANE CHISESI NFS. MD. PHD.,IRB,100,2024-07-05,2026-09-05,United States,No,https://clinicaltrials.gov/study/NCT06154590
NCT06176261,DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs,Phase 2,Recruiting,Interventional,Breast Cancer; Breast Cancer Female; Metastatic Triple-Negative Breast Carcinoma; ER Positive Breast Cancer; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; ER-negative Breast Cancer,Datopotamab Deruxtecan,,"Sarah Sammons, MD",Daiichi Sankyo,58,2024-01-08,2029-01-01,United States,No,https://clinicaltrials.gov/study/NCT06176261
NCT06184750,Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial,Phase 2,Recruiting,Interventional,Breast Atypical Ductal Hyperplasia; Breast Atypical Lobular Hyperplasia; Breast Carcinoma; Breast Ductal Carcinoma In Situ; Breast Lobular Carcinoma In Situ; Estrogen Receptor-Positive Breast Carcinoma,Biopsy Procedure; Biospecimen Collection; Mammography; Questionnaire Administration; Tamoxifen,,National Cancer Institute (NCI),,200,2024-09-27,2028-09-30,United States,No,https://clinicaltrials.gov/study/NCT06184750
NCT06224673,Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate (ADC)) for Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer,Phase 2,Not yet recruiting,Interventional,HER2 Low Breast Carcinoma; Triple Negative Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma,ARX788; Computed Tomography (CT); Biospecimen Collection; Amiloride,,"Laura Huppert, MD, BA","Ambrx, Inc.",36,2026-01-15,2029-03-31,United States,No,https://clinicaltrials.gov/study/NCT06224673
NCT06227377,"A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation",Phase 1,Recruiting,Interventional,Solid Tumors,QTX3034; Cetuximab,,Quanta Therapeutics,,250,2024-02-05,2027-04-01,United States,No,https://clinicaltrials.gov/study/NCT06227377
NCT06234397,"A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single Agent and in Combination With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Advanced or Metastatic Solid Tumors,BH3120; pembrolizumab,,Hanmi Pharmaceutical Company Limited,Merck Sharp & Dohme LLC,245,2023-12-28,2028-01-05,South Korea; United States,No,https://clinicaltrials.gov/study/NCT06234397
NCT06356311,"A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)",Phase 3,Recruiting,Interventional,Gastroesophageal Cancer,Sacituzumab tirumotecan; Trifluridine-Tipiracil; Irinotecan; Paclitaxel; Docetaxel; Rescue medication; Supportive care measures,,Merck Sharp & Dohme LLC,,450,2024-05-03,2027-05-06,Belgium; Brazil; Canada; Chile; China; Colombia; Denmark; France; Germany; Hong Kong; Israel; Italy; Japan; Malaysia; Mexico; Peru; Poland; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06356311
NCT06401889,Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy,,Recruiting,Observational,Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Breast Adenocarcinoma; Estrogen Receptor-Positive Breast Carcinoma; Progesterone Receptor-Positive Breast Carcinoma,Non-Interventional Study,,Mayo Clinic,,25,2024-07-19,2027-07-05,United States,No,https://clinicaltrials.gov/study/NCT06401889
NCT06428396,"A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastic Breast Cancer After Progression on Previous Endocrine Therapy (LITESPARK-029)",Phase 2,Recruiting,Interventional,Metastatic Breast Cancer,Belzutifan; Fulvestrant; Everolimus; Exemestane,,Merck Sharp & Dohme LLC,,120,2024-11-27,2028-10-07,Argentina; Canada; Chile; Colombia; South Korea; Taiwan; Thailand; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06428396
NCT06439693,"A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer: The SAPPHO Study",Phase 2,Recruiting,Interventional,Breast Cancer Female; Breast Cancer; Breast Cancer Metastatic; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Stage IV Breast Cancer,Nab-Paclitaxel; Paclitaxel; Docetaxel; Phesgo; T-DM1; Pertuzumab; Trastuzumab Deruxtecan; Trastuzumab Subcutaneous Subcutaneous; Tucatinib; Trastuzumab,,Dana-Farber Cancer Institute,Translational Breast Cancer Research Consortium; Johns Hopkins University,72,2024-08-08,2033-03-30,United States,No,https://clinicaltrials.gov/study/NCT06439693
NCT06473597,"A Comparison of Rimegepant Orally Disintegrating Tablet (Nurtec ODT) to Rizatriptan Benzoate Orally Disintegrating Tablet (Maxalt MLT-ODT) in Adult Patients Presenting to the ED With Migraine Headache: Randomized, Double-Blind, Clinical Trial",Phase 4,Recruiting,Interventional,Migraine,Rimegepant; Rizatriptan Benzoate,,Antonios Likourezos,,80,2024-09-01,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT06473597
NCT06525766,"Single Arm Pilot Trial of Adaptive Therapy (AT) With Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, Hormone Refractory Breast Cancer",Phase 2,Recruiting,Interventional,Anatomic Stage IV Breast Cancer AJCC v8; Estrogen-receptor-positive Breast Cancer; Metastatic HER2-Negative Breast Carcinoma; Metastatic Breast Cancer,Biospecimen Collection; Bone Scan; Capecitabine; Computed Tomography; Magnetic Resonance Imaging; Questionnaire Administration,,Mayo Clinic,,35,2025-10-01,2030-10-15,United States,No,https://clinicaltrials.gov/study/NCT06525766
NCT06538389,High Cannabidiol (CBD) Standardized Extract for Aromatase Inhibitor-Induced Arthralgia - A Randomized Controlled Double Blind Clinical Trial,Phase 2,Recruiting,Interventional,Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Breast Adenocarcinoma; Breast Ductal Carcinoma In Situ; Estrogen Receptor-Positive Breast Carcinoma; Progesterone Receptor-Positive Breast Carcinoma,Biospecimen Collection; BRC-001; Placebo Administration; Questionnaire Administration,,City of Hope Medical Center,National Cancer Institute (NCI); Biopharmaceutical Research Company,36,2024-08-26,2026-08-15,United States,No,https://clinicaltrials.gov/study/NCT06538389
NCT06555744,"A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,ZW191,,Zymeworks BC Inc.,,145,2024-10-30,2027-01-05,Australia; Japan; Singapore; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06555744
NCT06562192,"Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers",Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; HR+/HER2- Ductal and Lobular Breast Cancer; Triple Negative Breast Cancer; Colorectal Cancer,[68Ga]Ga-NNS309; [177Lu]Lu-NNS309,,Novartis Pharmaceuticals,,162,2024-10-15,2031-01-16,Belgium; Canada; France; Germany; Israel; Italy; Netherlands; Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06562192
NCT06572618,A Phase 2 Study of BTK Inhibitor Nemtabrutinib in Combination With Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma,Phase 2,Recruiting,Interventional,Mantle Cell Lymphoma,Biospecimen Collection; Bone Marrow Biopsy; Nemtabrutinib; Positron Emission Tomography and Computed Tomography Scan; Rituximab,,City of Hope Medical Center,National Cancer Institute (NCI),27,2025-01-22,2027-01-08,United States,No,https://clinicaltrials.gov/study/NCT06572618
NCT06590857,"Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) and Progressed After Antibody-drug Conjugates and/or Chemotherapy (TRACY-1).",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Breast Cancer; HER2-negative Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer,RYZ101,,"RayzeBio, Inc.",,124,2024-07-19,2033-01-05,United States,No,https://clinicaltrials.gov/study/NCT06590857
NCT06619236,"A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer",Phase 3,Recruiting,Interventional,Platinum-resistant Ovarian Cancer,Rina-S; Paclitaxel; Topotecan; Pegylated liposomal doxorubicin (PLD); Gemcitabine,,Genmab,,530,2025-02-07,2028-05-23,Australia; Austria; Belgium; Canada; Czechia; Denmark; France; Germany; Greece; Italy; Japan; Netherlands; Norway; Poland; Puerto Rico; Spain; United States,No,https://clinicaltrials.gov/study/NCT06619236
NCT06623201,Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas,Phase 1,Recruiting,Interventional,Basal Cell Carcinoma (BCC),aminolevulinic acid HCL (ALA); BLU-U device model 4170E,,Nathalie Zeitouni,,20,2024-10-07,2026-12-01,United States,No,https://clinicaltrials.gov/study/NCT06623201
NCT06630234,"A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3009 in Participants With Gastrointestinal Stromal Tumor (GIST)",Phase 1/Phase 2,Recruiting,Interventional,Gastrointestinal Stromal Tumor (GIST),DCC-3009,,"Deciphera Pharmaceuticals, LLC",,120,2024-12-10,2028-05-05,United States,No,https://clinicaltrials.gov/study/NCT06630234
NCT06677190,A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary or Clear Cell Carcinoma of Other Gynecologic Origin,Phase 2,Recruiting,Interventional,Ovarian Cancer; Ovarian Carcinoma; Endometrial Cancer; Uterine Cancer; Cervical Cancer; Vulvar Cancer; Gynecologic Cancer; Vaginal Cancer,Belzutifan,,Dana-Farber Cancer Institute,Merck Sharp & Dohme LLC,32,2024-12-20,2029-06-30,United States,No,https://clinicaltrials.gov/study/NCT06677190
NCT06678269,"A Phase I Study of Concurrent Abemaciclib and Radiation Therapy (RT) for Patients With Metastatic Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Breast Cancer",Phase 1,Recruiting,Interventional,Metastatic Breast Cancer; Stage IV Breast Cancer; Breast Cancer; Breast Cancer Stage IV; Breast Cancer Metastatic; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; Hormone-receptor-positive Breast Cancer,Abemaciclib; Radiation Therapy,,Memorial Sloan Kettering Cancer Center,Eli Lilly and Company,28,2024-11-15,2028-11-30,United States,No,https://clinicaltrials.gov/study/NCT06678269
NCT06695845,"A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)",Phase 2,Recruiting,Interventional,Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Urothelial Carcinoma; Salivary Gland Cancer; Pancreatic Cancer; HER-2 Protein Overexpression,Zanidatamab,,Jazz Pharmaceuticals,Jazz Pharmaceuticals Ireland Limited,200,2025-01-14,2027-12-31,South Korea; United States,No,https://clinicaltrials.gov/study/NCT06695845
NCT06712316,"A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer",Phase 2/Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,Pumitamig; Pembrolizumab; Carboplatin; Pemetrexed; Paclitaxel,,BioNTech SE,Biotheus Inc.,982,2025-01-07,2030-12-05,Australia; Belgium; China; France; Germany; Italy; Poland; Romania; South Korea; Spain; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06712316
